三生制药本次对外授权仅首付款就高达12.5亿美元,创下创新药企出海的首付款的新高,对于公司而言,这是实实在在的真金白银,大幅增加了公司的资金实力。公司也受到资本市场的追捧,年初以来最高涨幅超3倍,成为港股创新药板块股价表现最好的公司之一。5月20日,三生制药(01530.HK)发布公告,公司向国际制药巨头辉瑞公司达成首付款12.5亿美元、最高可达48亿美元的SSGJ-707创新药产品交易协议,以及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.